摘要
Abstract
Objective:To assess the clinical effects and safety of Chinese herb injection(CHI) combined gemcitabine and cisplatin ( GP) for non-small cell lung cancer( NSCLC).Methods:The relative randomized controlled trials ( RCTs) of CHIs were searched from Science Citation Index Expanded ( SCI-EXPANDED) ,PubMed,EMBASE, Cochrane Library, CancerLit, Chinese Knowledge Infrastruc-ture(CNKI), Chinese Scientific Journals Fulltext Database(VIP-CSJFD),Chinese Biomedical Literature Database(CBM),Wan-Fang Database( WANFANG) ,Chinese Science Citation Database( CSCD) and Traditional Chinese Medical Database System.The related refer-ences and website were also traced.The RCTs were screened according to the predefined inclusion and exclusion criteria, the related items were used to assess the quality of RCTs, data were analyzed by WinBugs software.Results:61 RCTs including 4480 patients and 12 CHIs were finally included.The quality of included RCTs were not high.The results of network Meta-analyses showed that,combined with GP, there were significant difference between compound matrine injection and ranglaite injection in efficacy,aidi injection and ranglaite injec-tion in efficacy, compound matrine injection and kanglaite injection in nausea and vomiting, aidi injection and kanglaite injection in nau-sea and vomiting,but no difference between other CHIs in efficacy and nausea and vomiting.At the same time, there were no difference between 12 CHIs in quality of life and leukopenia.Conclusion:Based on the results of network Meta-analysis and rank,chansu injection, xiao'aiping injection and kangai injection were more than other 9 CHIs.关键词
中药注射剂/吉西他滨/顺铂/非小细胞肺癌/网状Meta分析Key words
Chinese traditional medicine injection/Gemcitabine/Cisplatin/Non-small cell lung cancer/Network Meta-analysis分类
医药卫生
